Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 23, 2026Journal of Crohn s and Colitis

DOP012Fecal calprotectin predicts relapse in ulcerative proctitis: a 12-month prospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

RIR Ferreiro IglesiasLNLaura Nieto‐GarcíaMPM L De Castro Parga

Discussion

Loading...

Member takes

Overview

Prospective cohort study evaluates fecal calprotectin's role in predicting relapse in ulcerative proctitis, suggesting its clinical utility.

Key Points

  • To evaluate the efficacy of fecal calprotectin in predicting clinical relapse in patients with ulcerative proctitis during a 12-month follow-up.
  • Conducted a multicenter, prospective, observational study
  • Included patients aged ≥18 with ulcerative proctitis under maintenance treatment
  • Assessed sociodemographic data and fecal calprotectin at months 6 and 12
  • Used ROC curve and multivariable logistic regression to analyze predictive value
  • 186 patients with ulcerative proctitis were analyzed
  • 29 patients (16%) experienced clinical relapse during follow-up
  • Mean fecal calprotectin levels were significantly higher in relapsing patients (632 µg/g) compared to non-relapsing (116 µg/g)
  • The optimal fecal calprotectin cutoff for predicting relapse was identified as 40 µg/g
  • Fecal calprotectin ≥ 40 µg/g was an independent predictor of clinical relapse with an odds ratio of 1.9

Cite This Study

Iglesias et al. (2026) studied this question.

synapsesocial.com/papers/69731047c8125b09b0d1ff68https://doi.org/10.1093/ecco-jcc/jjaf231.049
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1DOP032Comparative study on the effectiveness, durability, and safety of upadacitinib versus risankizumab after anti-TNF failure in Crohn’s Disease: The U-PARIS study of ENEIDA2026
  2. 2P0716Safety of biologic and small molecule therapies in IBD patients with previous cancer: risk of recurrence or new neoplasia2026
  3. 3DOP071Multi-omics biomarkers for predicting treatment response in inflammatory bowel disease2026
  4. 4P0734Quality of life and mucosal healing in Ulcerative Colitis: CAVI_CU prospective study by GETECCU2026
  5. 5P0724Efficacy and safety of granulocyte and monocyte apheresis (GMA) with Adacolumn® in patients with inflammatory bowel disease in real-world practice in Spain: the GRACE study.2026 · 1 citations